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Abstract
Background: T-cell interferon-gamma release assays (IGRAs) may have a role in the diagnosis of active tuberculosis
when evaluating patients for whom standard microbiology has limited sensitivity. Our objective was to examine
the accuracy of a commercial IGRA for diagnosis of active tuberculosis in HIV-infected persons.
Methods: We enrolled HIV-infected patients admitted to Mulago Hospital in Kampala, Uganda with cough ≥ 2
weeks. All patients underwent standard medical evaluation. We collected peripheral blood specimens at enrollment
and performed a commercial, ELISPOT-based IGRA according to the manufacturer’s recommendations. IGRA
sensitivity and specificity were determined using mycobacterial culture results as the reference standard.
Results: Overall, 236 patients were enrolled. The median CD4+ T-lymphocyte count was 49 cells/μl and 126 (53%)
patients were diagnosed with active pulmonary tuberculosis. IGRAs were not performed in 24 (10%) patients due
to insufficient mononuclear cell counts. In the remaining 212 patients, results were indeterminate in 54 (25%).
IGRAs were positive in 95 of 158 (60%) patients with interpretable results. The proportion of positive test results
was similar across CD4+ count strata. IGRA sensitivity was 73% and specificity 54%. IGRA results did not
meaningfully alter the probability of active tuberculosis in patients with negative sputum smears.
Conclusions: An ELISPOT-based IGRA detected a high prevalence of latent tuberculosis infection in a hospitalized
population of tuberculosis suspects with advanced HIV/AIDS but had limited utility for diagnosis of active
tuberculosis in a high prevalence setting. Further research is needed to identify stronger and more specific
immune responses in patients with active tuberculosis.
Background
T-cell interferon-gamma release assays (IGRAs) measure
interferon-gamma release by sensitized T-lymphocytes
stimulated with Mycobacterium tuberculosis (M. TB)-
specific antigens. Though IGRAs are highly accurate for
diagnosis of latent tuberculosis infection (LTBI) [1],
their use as a diagnostic tool for active tuberculosis (TB)
poses several challenges. IGRAs measure the host
immune response to M. TB rather than the presence or
absence of the organism in clinical specimens. In addi-
tion, IGRAs cannot distinguish an immune response to
current active TB from an immune response to prior
disease or latent infection [2]. However, standard micro-
biologic tests (smear microscopy, nucleic acid amplifica-
tion tests, and mycobacterial culture) also have well
known limitations, particularly in patients co-infected
with HIV [3,4]. Such patients more commonly present
with atypical clinical and radiographic findings and
pauci-bacillary disease [5]. The consequences of missing
a diagnosis are also greater, as the disease is more likely
to progress rapidly [6].
We hypothesized that the high sensitivity of IGRAs for
detecting M. TB infection may help clinicians rule out a
d i a g n o s i so fa c t i v eT Bi np a t i e n t sc o - i n f e c t e dw i t hH I V .
In previous studies of HIV-infected adults, the sensitivity
of commercial IGRAs for diagnosing active TB has ran-
ged from 85-93%. [7-10] However, none of these studies
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patients with advanced HIV-related immunosuppression.
In addition, the clinical utility of IGRAs in smear-nega-
tive TB suspects has not been assessed adequately. In
smear-negative patients, a negative IGRA result might
decrease the probability of TB sufficiently to allow clini-
cians to withhold empiric TB therapy and/or pursue
alternative diagnoses.
To address our hypothesis, we conducted a prospec-
tive, blinded evaluation of T-SPOT.TB® (Oxford Immu-
notec, Oxford, UK), an FDA-approved, enzyme-linked
immunospot (ELISPOT)-based IGRA, for the diagnosis
of pulmonary TB in HIV-infected TB suspects admitted
to Mulago Hospital in Kampala, Uganda. We chose to
evaluate an ELISPOT-based IGRA due to higher sensi-
tivity compared with enzyme-linked immunosorbent
assay (ELISA)-based tests. [11-13]
Methods
Study population
We screened consecutive patients admitted to the medi-
cal wards of Mulago Hospital in Kampala, Uganda to
identify those persons presenting with cough ≥ 2w e e k s
duration (defined as pulmonary TB suspects). We
enrolled all pulmonary TB suspects who were HIV-
infected, not on anti-TB treatment, and provided
informed consent. We excluded patients from this ana-
lysis if sputum acid-fast bacillus (AFB) smear results
were unavailable or TB status could not be established
due to mycobacterial culture contamination (at least
two negative cultures were required to exclude TB).
Institutional review boards at Makerere University,
Mulago Hospital, the Uganda National Council for
Science and Technology, and the University of Califor-
nia, San Francisco approved the study protocol.
Patient evaluation
All patients underwent standard medical evaluation. We
collected sputum specimens at enrollment (on the morn-
ing after hospital admission) and on the subsequent morn-
ing for AFB smear examination (direct Ziehl-Neelsen
microscopy) and Lowenstein-Jensen culture, as previously
described [14]. All patients with negative AFB microscopy
results underwent bronchoscopy with bronchoalveolar
l a v a g e( B A L )i fr e f e r r e db yt he treating ward physician.
Trained laboratory technicians examined BAL samples for
the presence of mycobacteria (AFB smear examination
and Lowenstein-Jensen culture), Pneumocystis jirovecii,
and other fungi [15]. We determined CD4+ T-lymphocyte
counts in all enrolled patients.
T-SPOT.TB assays
We performed and interpreted all assays according to
the manufacturer’s recommendations. At the time of
enrollment, a study officer collected approximately 16
mL of blood for the T-SPOT.TB assay in anticoagulant-
citrate-dextrose tubes. Trained laboratory technicians at
the Joint Clinical Research Centre (JCRC) who were
blinded to patients’ clinical status processed all blood
samples within 6 hours of collection. Peripheral blood
mononuclear cells (PBMCs) were isolated using ficoll-
hypaque gradient centrifugation and cell count and via-
bility were determined using a Guava automated coun-
ter (Guava Technologies, Hayward, CA). IGRAs were
performed only when PBMC viability was greater than
80%. Spots were counted using an automated ELISPOT
reader (Immunospot Analyzer, Cellular Technologies,
Ltd. Cleveland, OH). We considered IGRA results to be
positive if: 1) the negative control had < 5 spots and
wells stimulated with test Panel A (containing ESAT-6
antigen) or Panel B (containing CFP-10 antigen) had 6
or more spots or 2) the negative control had 5-10 spots
and wells stimulated with test Panel A or Panel B had at
least twice the number of spots in the negative control.
We considered IGRA results to be indeterminate if the
negative control spot count was > 10 (high background)
or if the positive mitogen control spot count was < 20.
Outcome classification
We defined the reference standard for active TB as a
positive mycobacterial culture result on any sputum or
BAL fluid specimen (culture-positive TB). Cultures were
interpreted without knowledge of IGRA results.
Quality control
The JCRC laboratory is the central laboratory for the
National Institutes of Health (NIH)-funded HIV Vaccine
Prevention Trials Network, and the technicians have
over 10 years of experience performing ELISPOT assays.
Study investigators (AC and HC) received on-site train-
ing in the performance of the T-SPOT.TB assay from
the manufacturer. These investigators conducted T-
SPOT.TB training of JCRC technicians and supervised
the T-SPOT.TB assays for the study.
Statistical analysis
We performed bivariate analyses using the chi-squared
test for dichotomous variables and the Mann-Whitney
rank-sum test for continuous variables. We calculated
sensitivity and specificity of all diagnostic tests using
mycobacterial culture results as a reference standard.
We compared the sensitivity and specificity of sputum
AFB smear and IGRA using McNemar’s test. To deter-
mine the clinical utility of IGRAs for the diagnosis of
active pulmonary TB, we determined the post-test prob-
ability of TB. In this analysis, we considered the pre-test
probability of TB to be equal to the TB prevalence in
the study population. We then calculated likelihood
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portion of patients with a given result in those with dis-
ease over the proportion of patients with the result in
those without disease. Finally, we determined the post-
test probability of TB by converting the pre-test prob-
ability of TB to odds, multiplying by the likelihood ratio,
and converting the resulting post-test odds back to
probability. We performed all analyses using STATA
10.0 (Stata Corporation, College Station, Texas), with
the level of significance specified in reference to a two-
tailed, type I error (p-value) less than 0.05.
Results
Study population
Of 244 eligible patients enrolled, 8 (3%) were excluded
from the analysis because either AFB smear results were
unavailable (n = 4) or mycobacterial cultures were con-
taminated (n = 4) (Figure 1). Baseline characteristics
(gender, age, antiretroviral use, CD4+ T-lymphocyte
count were not significantly different between excluded
and included patients (p > 0.2 for all comparisons).
The reference standard outcome of culture-positive TB
was confirmed in 126 of 236 (53%) patients (Table 1).
The diagnosis was confirmed by sputum culture in 123
patients and BAL fluid culture in 3 patients. CD4+ T-
lymphocyte counts were below 200 cells/μl in greater
than 75% of patients overall. However, median CD4+ T-
lymphocyte counts were approximately twice as high in
patients without TB compared to those with TB (75
cells/μl vs. 39 cells/μl, p = 0.01). Baseline characteristics
were otherwise similar between the two groups.
IGRA results
IGRAs were not performed in 24 (10%) patients with an
inadequate number of PBMCs. IGRA results were inde-
terminate in 54 patients (25%) either due to a low mito-
gen response (n = 7) or high background response (n =
47). The proportion of indeterminate test results
declined significantly when comparing patients with a
CD4+ T-lymphocyte count ≤ 50 cells/μl (33/109, 30%),
51-200 cells/μl (15/60, 25%), and > 200 cells/μl( 6 / 4 3 ,
14%) (p = 0.03). Other demographic and clinical charac-
teristics (gender, age, antiretroviral use, TB status) were
also similar in patients with and without indeterminate
IGRA results (p > 0.2 for all comparisons). Patients with
indeterminate results had higher in-hospital mortality
(17% vs. 8%, p = 0.05).
IGRAs were positive in 95 of 158 (60%) patients with
interpretable results. There was no difference in the pro-
portion of positive test results among patients with a
CD4+ T-lymphocyte count ≤ 50 cells/μl (44/76, 58%),
51-200 cells/μl (30/45, 67%), and > 200 cells/μl( 2 1 / 3 7 ,
Figure 1 Study population. Of 244 patients eligible for the study, 236 (97%) were included. Pulmonary tuberculosis, defined as ≥ 1 positive
culture result, was diagnosed in 126 (53%) patients.
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higher in patients with active TB compared to those
without active TB after both ESAT-6 (42 vs. 2, p < 0.001)
and CFP-10 stimulation (11 vs. 3, p = 0.03) (Figure 2).
Diagnostic performance
For diagnosing active pulmonary TB, IGRA sensitivity
was 73% (95% CI 62-82%) and specificity 54% (42-66%)
(Table 2). Sensitivity (78% vs. 67%, difference 11%, 95%
CI -8% to +29%, p = 0.27) was higher among AFB
smear-positive compared to smear-negative patients, but
this difference was not statistically significant. Specificity
was similar between the two groups. Controlling for the
degree of HIV-related immunosuppression by dividing
spot counts by CD4+ T-lymphocyte count [9] did not
improve diagnostic accuracy compared to classifying
results based on spot counts alone (for ESAT-6, CFP-10,
or combined ESAT-6 and CFP-10 results; p > 0.2 for all
comparisons).
We next assessed the diagnostic utility of IGRAs
according to AFB smear status by calculating the post-
test probability of TB in patients with positive and nega-
tive IGRA results (Table 3). In this analysis, we defined
pre-test probability as the TB prevalence in the study
population: 94% for AFB smear-positive patients and
37% for AFB smear-negative patients. As expected,
IGRA results did not meaningfully alter the probability
of disease among AFB-smear positive patients. A posi-
tive IGRA result increased the probability of TB from
94% to 96% while a negative IGRA result decreased the
probability of TB from 94% to 87%. More importantly,
IGRA results did not contribute to a clinically meaning-
ful change in the post-test probability of TB in AFB
smear-negative patients. A positive IGRA result
increased the probability of TB from 37% to 47% while
a negative IGRA result decreased the probability of TB
from 37% to 26%.
Discussion
In this study, we found that an ELISPOT-based IGRA
was positive in 60% of patients in a Ugandan sample of
hospitalized, HIV-infected patients, indicating a high
prevalence of M. TB infection. IGRA positivity was not
affected by CD4+ T-lymphocyte count in our population
with advanced immunosuppression. The test had mod-
erate to high sensitivity but poor specificity in the diag-
nosis of active pulmonary TB. In AFB smear-negative
patients, negative IGRA results did not lead to a clini-
cally meaningful decrease in the probability of active
disease. In low-income countries with high HIV preva-
l e n c e ,t h e s ef i n d i n g ss u g g e s tar o l ef o rI G R A si nL T B I
screening programs but not as a rule-out test for active
TB in symptomatic patients.
Numerous studies have evaluated the sensitivity of T-
S P O T . T B-t h eo n l yc o m m e r c i a l l ya v a i l a b l eE L I S P O T -
based IGRA - for diagnosis of active pulmonary TB and
results have been similar in immunocompetent (83-
100%) and HIV-infected patients (85-93%)
[7,8,10,12,16-19]. There are at least two potential expla-
nations for the slightly lower sensitivity (73%) seen in
our study. The spectrum of diseased and non-diseased
patients enrolled in many studies differed from that
seen in clinical practice, a factor known to inflate sensi-
tivity estimates [20,21]. In addition, our HIV-infected
study population was hospitalized and severely immuno-
suppressed, with more than 75% patients having a
CD4+ T-lymphocyte count < 200 cells/μl. Of note, sen-
sitivity was not increased by forming a ratio between
ESAT-6 or CFP-10 spot counts and CD4+ T-lympho-
cyte count, an area of contention in the literature [8,9].
The specificity of T-SPOT.TB for active pulmonary TB
has ranged from 45-95%, with studies in both low burden
[8,10,17,18] and high burden[22] countries reporting
values below 65%. The low specificity (54%) for active TB
in our setting is not surprising given the known high pre-
valence of LTBI in Kampala. Current generation inter-
feron-gamma release assays cannot distinguish immune
responses among patients with latent infection, prior
active disease, and current active disease when performed
using peripheral blood specimens [2]. Further studies are
needed to determine whether local immune responses
can better distinguish active from latent infection
[18,23-25] and to identify antigens that elicit immune
responses more specific for current active disease [23].
A diagnostic test should substantially change the pre-
test probability of disease and influence treatment
Table 1 Demographic and clinical characteristics.
Characteristic Overall
(N = 236)
Tuberculosis
(N = 126)
No Tuberculosis
(N = 110)
p-value
Male, N (%) 112 (47) 61 (48) 51 (46) 0.80
Median age (IQR) 33 (27-40) 32 (27-39) 34 (27-41) 0.25
Median CD4+ T-lymphocyte count (IQR) 49 (16-160) 39 (15-107) 75 (19-215) 0.01
Anti-retroviral use, N (%) 40 (17) 17 (13) 23 (21) 0.16
In-hospital mortality, N (%) 24 (10) 13 (10) 11 (10) 1.0
Abbreviations: IQR, inter-quartile range
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Page 4 of 7Figure 2 ESAT-6 and CFP-10 spot counts in patients with and without tuberculosis. The box plots show the distribution of spot forming
cells after stimulation with ESAT-6 (top panel) and CFP-10 (bottom panel). Median spot counts were significantly higher in patients with active
TB compared to those without active TB after both ESAT-6 (42 vs. 2, p < 0.001) and CFP-10 stimulation (11 vs. 3, p = 0.03).
Table 2 Sensitivity and specificity of T-SPOT.TB
Overall
(N = 158)
AFB Smear-Positive
(N = 45)
AFB Smear-Negative
(N = 113)
p-value
% Sensitivity (95% CI) 73 (62-82) 78 (62-89) 67 (52-81) 0.27
% Specificity (95% CI) 54 (42-66) 50 (7-93) 54 (42-66) 0.87
Abbreviations: AFB, acid-fast bacilli.
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ing TB suspects with negative AFB smears, clinicians
are faced with a decision to either initiate or withhold
empiric therapy. IGRAs could be useful in this situation
if a negative result decreased the probability of TB
below a threshold at which most clinicians would be
comfortable withholding treatment. Based on the test
characteristics reported in our study, a negative IGRA
result would decrease the probability of TB below 10%
only when the prevalence of TB among smear-negative
patients is already at or below 15%. Moreover, a high
proportion of indeterminate results further limited the
clinical utility of IGRAs in our setting.
Our study has several potential limitations. First, the
proportion of indeterminate results is higher than in
previous studies despite stringent quality control proce-
dures. Higher background levels of non-specific immune
activation have been observed in Uganda compared to
North American cohorts (David M. Lewinsohn, personal
communication). It is also possible that non-specific
immune activation was more common in our hospita-
lized population with advanced illness. Second, myco-
bacterial culture on Lowenstein-Jensen media is an
imperfect reference standard. A more sensitive culture
technique (such as liquid culture) may have decreased
the number of false positive IGRA results and increased
t h en u m b e ro ft r u ep o s i t i v er e s u l t s ,r e s u l t i n gi nh i g h e r
sensitivity and specificity [26]. In addition, we did not
perform speciation tests to exclude the possibility of iso-
lating non-tuberculous mycobacteria. Finally, our study
population consisted of hospitalized patients with
advanced HIV infection. The point estimates of sensitiv-
ity and specificity reported here may not generalize to
ambulatory or predominantly HIV-uninfected popula-
tions. Nevertheless, our findings are consistent with pre-
vious studies.
Conclusions
An ELISPOT-based IGRA detected a high prevalence of
M. TB infection in a population of TB suspects with
advanced HIV infection in Uganda. These assays should
be considered in sub-Saharan Africa when screening
HIV-infected patients for latent tuberculosis infection.
However, current ELISPOT-based IGRAs are unlikely to
have clinical utility when evaluating active TB suspects.
Further research and innovation is needed to identify M.
tuberculosis antigens and host markers that are more
sensitive and specific for active tuberculosis.
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